[go: up one dir, main page]

UY31232A1 - Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones - Google Patents

Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Info

Publication number
UY31232A1
UY31232A1 UY31232A UY31232A UY31232A1 UY 31232 A1 UY31232 A1 UY 31232A1 UY 31232 A UY31232 A UY 31232A UY 31232 A UY31232 A UY 31232A UY 31232 A1 UY31232 A1 UY 31232A1
Authority
UY
Uruguay
Prior art keywords
group
dibenzotifenilamino
cromen
isomers
replaced
Prior art date
Application number
UY31232A
Other languages
English (en)
Inventor
Niall Morrison Barr Martin
Sylvie Gomez
Heather Mary Ellen Duggan
Christine Sarah Bailey
Marc Geoffrey Hummersone
Keith Allan Menear
Frigerio Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31232A1 publication Critical patent/UY31232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuestos de la formula I, en donde: R1 y R2 se seleccionan de manera independiente entre hidrogeno, un grupo alquilo C1-7, un grupo heterociclilo C3-20 o arilo C5-20 opcionalmente sustituido, o juntos pueden formar, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalemente sustituido que tiene entre 4 y 8 átomos de anillo; X es CH o N; n es 1 o 2; RC1 y Rc2 se seleccionan de manera independiente entre H y metilo; cuando X es N, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido y sulfonilo; y cuando X es CH, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido, sulfonilo, amino y éter.
UY31232A 2007-07-19 2008-07-17 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones UY31232A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95063107P 2007-07-19 2007-07-19
US3656008P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
UY31232A1 true UY31232A1 (es) 2009-03-02

Family

ID=39791057

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31232A UY31232A1 (es) 2007-07-19 2008-07-17 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Country Status (14)

Country Link
US (1) US20090042865A1 (es)
EP (1) EP2176254A1 (es)
JP (1) JP2010533694A (es)
KR (1) KR20100063701A (es)
CN (1) CN101754964A (es)
AR (1) AR067613A1 (es)
AU (1) AU2008277418A1 (es)
BR (1) BRPI0814797A2 (es)
CA (1) CA2693926A1 (es)
CL (1) CL2008002130A1 (es)
RU (1) RU2009149210A (es)
TW (1) TW200918528A (es)
UY (1) UY31232A1 (es)
WO (1) WO2009010761A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
CN1867566B (zh) * 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
CN101061111A (zh) * 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
IN2014KN02601A (es) 2012-04-24 2015-05-08 Vertex Pharma
PT2970218T (pt) 2013-03-12 2019-03-01 Vertex Pharma Inibidores de adn-pk
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
CN111053903A (zh) * 2019-12-26 2020-04-24 深圳市纳诺艾医疗科技有限公司 一种携带共振原子的核酸类似物的化合物的应用
WO2022148354A1 (zh) * 2021-01-05 2022-07-14 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
JP3521145B2 (ja) * 1993-04-09 2004-04-19 富山化学工業株式会社 免疫調節剤，細胞接着阻害剤および自己免疫疾患の治療・予防剤
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP4103968B2 (ja) * 1996-09-18 2008-06-18 株式会社半導体エネルギー研究所 絶縁ゲイト型半導体装置
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
ATE491703T1 (de) * 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
CN1867566B (zh) * 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
CN101061111A (zh) * 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
JP5781720B2 (ja) * 2008-12-15 2015-09-24 ルネサスエレクトロニクス株式会社 半導体装置及び半導体装置の製造方法

Also Published As

Publication number Publication date
BRPI0814797A2 (pt) 2015-02-03
RU2009149210A (ru) 2011-08-27
JP2010533694A (ja) 2010-10-28
CN101754964A (zh) 2010-06-23
EP2176254A1 (en) 2010-04-21
US20090042865A1 (en) 2009-02-12
AU2008277418A1 (en) 2009-01-22
AR067613A1 (es) 2009-10-14
TW200918528A (en) 2009-05-01
CL2008002130A1 (es) 2009-01-02
CA2693926A1 (en) 2009-01-22
KR20100063701A (ko) 2010-06-11
WO2009010761A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
UY31232A1 (es) Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
PH12012501532A1 (en) Di-substituted pyridine derivatives as anticancers
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
JO2947B1 (en) Compounds corresponding to cyclopamine
ES2530398T3 (es) Pirrolidin-2-onas 4-sustituidas y su uso
ZA200601595B (en) Aminopyrones and their use as ATM inhibitors
MX2016014238A (es) Composicion limpiadora.
NO20071873L (no) DNA-PK inhibotorer.
MY152972A (en) Azabicyclo compound and salt thereof
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
MX2015007883A (es) Compuestos para protección de células.
MX2010007593A (es) Derivados novedosos de acil cianopirrolidinas.
MX2016014239A (es) Composicion limpiadora.
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
CO6320143A1 (es) Nuevos derivados dihidroindolonas su procedimeinto de preparacion y composiciones farmaceuticas que los contienen
CY1117560T1 (el) Νεο υποκατασταθεν παραγωγο ισοκινολινης
AR060379A1 (es) Compuesto y composicion herbicida
GB2470170A (en) Dithienothiophene derivatives
ATE528284T1 (de) Metallcarbamate aus tolylendiaminen
IN2012DN01251A (es)
ES2546833T3 (es) Derivados de pirrolidina como antagonistas de receptores de NK-3
CR20110306A (es) Derivados de morfina-6-glucuronido, su preparación y su aplicación en terapéutica
MX2009004075A (es) Derivados de alfa-, omega-aminoalcohol, enriquecidos en enantiomeros, su preparacion y uso como agentes repelentes de insectos y acaros.
ES2531049T3 (es) Preparado estabilizado de 3,3-dialcoxi-1-propeno

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171009